NCT04347161Active, not recruiting
Implementation Strategies for Monitoring Adherence in Real Time
Source: ClinicalTrials.gov · Last updated 4 Mar 2026
Brief summary (registry, in English)
The objective of this project is to identify effective strategies to help patients with lung cancer manage side effects and achieve optimal adherence to oral targeted therapies. To achieve this objective, we will evaluate the effect of a novel, bidirectional conversational agent, compared to usual care, on adherence to oral targeted therapies using a two-arm randomized controlled trial, and explore how multilevel factors impact the acceptability and effectiveness of this strategy by collecting qualitative and quantitative data from clinicians and patients.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 75 (actual)
- First submitted
- 1 Apr 2020
- Start date
- 22 Feb 2021
- Primary completion date
- 30 Nov 2022
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Diseases
- Lung cancer
- NCT number
- NCT04347161
What you commit to
- Study type: Interventional
- Participants enrolled: 75
- From 22 Feb 2021 to the primary completion date, 30 Nov 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent enrollment in a therapeutic clinical trial
- Taking more than one oral targeted therapy or concurrent chemotherapy during the study window
Other
- Inability to respond to questions and engage with "Penny" in English
- Inability or unwillingness to provide informed consent to participate in the study
- Inability to engage with SMS text-messaging platform
- Lack of approval from the patient's oncologist
Who the study is looking for
- Adult patient (age \> 18 years) with NSCLC at UPHS who is receiving one of the following nine oral therapies: afatinib, erlotinib, dacomitinib, gefitinib, osimertinib, alectinib, brigatinib, crizotinib, or lorlatinib.
- Patient possession of a mobile device that can send/receive SMS texts
- Ability to respond to questions and engage with "Penny" in English
- Ability to provide informed consent to participate in the study
- Approval from the patient's medical oncologist to be approached
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.